BUSINESS

Teva Takeda Yakuhin Applies for Pediatric Use for Blopress Based on Information in Public Domain

December 7, 2018
Teva Takeda Yakuhin announced on December 6 that it has applied for a pediatric indication based on information in the public domain for the angiotensin receptor blocker (ARB) Blopress Tablets (candesartan). The Japanese Society of Pediatric Cardiology and Cardiac Surgery…

To read the full story

BUSINESS

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…